Labopat launches Techcyte Fusion across histology and cervical cytology in Mexico

By AI, Created 8:26 PM UTC, May 26, 2026, /AGP/ – Labopat diagnostics® is now live on Techcyte Fusion® across histology and cervical cytology workflows, expanding digital pathology access in Mexico. The rollout is aimed at easing pathologist and cytotechnologist shortages while supporting remote review, collaboration, and faster diagnostics.

Why it matters: - Mexico faces a shortage of trained pathologists and cytotechnologists. - Labopat’s move to a unified digital pathology platform is meant to expand access to expertise and help handle rising diagnostic demand. - The deployment also supports remote case review and collaboration, which can improve access to care across different locations.

What happened: - Techcyte announced that Labopat diagnostics®, a Mexico-based diagnostic services provider, is now live on the Techcyte Fusion platform. - The implementation covers both histology and cervical cytology workflows. - Labopat has nearly 40 years of experience in diagnostic services. - Labopat CEO Sergio Sanchez said the rollout supports the company’s mission to deliver confident diagnostics and manage increasing case volumes.

The details: - Techcyte Fusion is designed to unify histology and cytology in a single workflow environment. - Labopat pathologists will be able to review histology and cytology cases in the same platform. - The platform has also been used for tele-diagnostic frozen-section support in intraoperative procedures. - Techcyte said that use case can improve turnaround time for surgeons. - Dr. Tiffany Chen, Techcyte’s chief medical officer, said Labopat joins a growing group of laboratories adopting digital pathology to address real-world challenges. - Techcyte says its platform digitizes lab workflows and offers AI tools intended to improve efficiency and diagnostic accuracy.

Between the lines: - The rollout reflects a broader shift toward digital pathology as laboratories try to offset workforce constraints without lowering diagnostic standards. - Labopat’s emphasis on ethics, technology, and patient needs signals that the company is positioning AI-enabled workflows as a clinical quality tool, not just an efficiency upgrade. - The combination of unified workflows and remote review suggests digital pathology is becoming part of routine service delivery, not only specialized consultation.

What’s next: - Labopat is expected to continue expanding AI-based digital workflows as diagnostic demand grows. - Broader digital pathology adoption could give more laboratories a template for addressing staffing gaps and extending specialist access. - Techcyte is continuing to push a unified anatomic and clinical pathology platform through partnerships with labs, scanners, AI vendors, and diagnostic companies.

The bottom line: - Labopat’s launch on Techcyte Fusion is another sign that digital pathology is moving from pilot projects to operational infrastructure in Latin American diagnostics.